Cwm LLC Reduces Stake in Koninklijke Philips (NYSE:PHG)

Cwm LLC decreased its stake in shares of Koninklijke Philips (NYSE:PHG) by 10.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 15,170 shares of the technology company’s stock after selling 1,814 shares during the period. Cwm LLC’s holdings in Koninklijke Philips were worth $354,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Sequoia Financial Advisors LLC purchased a new stake in Koninklijke Philips during the 4th quarter worth about $473,000. HighTower Advisors LLC raised its holdings in shares of Koninklijke Philips by 73.9% in the 3rd quarter. HighTower Advisors LLC now owns 28,270 shares of the technology company’s stock valued at $562,000 after acquiring an additional 12,010 shares in the last quarter. abrdn plc purchased a new stake in shares of Koninklijke Philips in the 4th quarter valued at about $2,677,000. Barclays PLC purchased a new stake in shares of Koninklijke Philips in the 3rd quarter valued at about $2,310,000. Finally, Glenmede Trust Co. NA raised its holdings in shares of Koninklijke Philips by 53.5% in the 3rd quarter. Glenmede Trust Co. NA now owns 34,065 shares of the technology company’s stock valued at $679,000 after acquiring an additional 11,875 shares in the last quarter. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Price Performance

PHG opened at $26.56 on Friday. The stock’s 50 day simple moving average is $20.95 and its 200 day simple moving average is $21.12. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.20 and a quick ratio of 0.78. Koninklijke Philips has a 1 year low of $17.75 and a 1 year high of $29.44. The firm has a market cap of $24.66 billion, a price-to-earnings ratio of -27.67, a PEG ratio of 1.37 and a beta of 0.75.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Koninklijke Philips had a positive return on equity of 9.82% and a negative net margin of 4.41%. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.47 billion. As a group, analysts predict that Koninklijke Philips will post 1.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on PHG shares. StockNews.com raised Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. raised Koninklijke Philips from an “underweight” rating to a “neutral” rating in a report on Tuesday. BNP Paribas cut Koninklijke Philips from an “outperform” rating to an “underperform” rating in a report on Wednesday, February 7th. Finally, UBS Group raised Koninklijke Philips from a “sell” rating to a “neutral” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $19.00.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.